BCB Bancorp, Inc. Reports Net Loss of $12.0 Million in Fourth Quarter 2025 BAYONNE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), today reported a net loss of $12.0 million for the fourth quarter of 2025, compared to net income of $4.3 million in the third quarter of 2025, and net income of $3.3 million for the fourth quarter of 2024. The Company’s loss per diluted share for the fourth quarter was ($0.73) compared to earnings per diluted share of $0.22 in the preceding quarter and $0.16 i...
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activityLitifilimab has the potential to be a first-in-class therapy targeting blood dendritic cell antigen 2 (BDCA2) in CLE, a chronic autoimmune skin disease that has a substantial impact on the daily life of patients, and may result in permanent scarring and dis...
America’s Car-Mart Advances SG&A Cost Control Strategy With Phase 2 Store Consolidations Consolidates 13 additional locations to continue modernizing the business, better utilize inventory and teams, and strengthen performance at remaining locations. ROGERS, Ark., Jan. 13, 2026 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“Car-Mart” or the “Company”) today announced the completion of Phase 2 of its previously announced SG&A Cost Control Strategy through footprint optimization, which includes the consolidation of 13 locations into higher-performing nearby dealerships. Thi...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Biogen Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 9 January 2026 in which we reassessed the appropriateness of the ratings in the context of the ...
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen is dedicated to partnering with the SMA community to advance care through scientific innovation and a commitment to enhancing outcomes for people living with SMA CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) today announced the European Commission (EC...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.